Skip to main content
SpringerLink
Log in

Ablative Techniques for CRLM: Alone or in Association

  • Chapter
  • First Online:
Colorectal Cancer Liver Metastases

  • 921 Accesses

Abstract

Despite improved systemic therapies, surgical techniques, and perioperative care in the management of colorectal liver metastasis (CRLM), most patients still remain ineligible for surgical resection, which is the standard of care, and require alternative techniques for local control of the disease. Ablative techniques for the treatment of CRLM offer a less invasive treatment route and can be used alone or in association with resection and/or chemotherapy. In general, they can be divided into thermal and nonthermal techniques. Thermal techniques deliver energy to the tumor site in order to increase or decrease local temperatures to cytotoxic levels. The most widely used ablative techniques include radiofrequency ablation (RFA) and microwave ablation (MWA). MWA has increased utilization due to less heat-sink, potential to address larger lesions, and less time required. Combining surgical resection and ablation simultaneously is safe and could allow more patients to undergo potentially curative therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pillai K, Akhter J, Chua TC, et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore). 2015;94(9):e580. https://doi.org/10.1097/MD.0000000000000580.

    Article  Google Scholar 

  2. Garrean S, Hering J, Helton WS, Espat NJ. A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. Am J Surg. 2007;194(1):79–88. https://doi.org/10.1016/j.amjsurg.2006.11.025.

    Article  PubMed  Google Scholar 

  3. Knavel EM, Brace CL. Tumor ablation: common modalities and general practices. Tech Vasc Interv Radiol. 2013;16(4):192–200. https://doi.org/10.1053/j.tvir.2013.08.002.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Vogl TJ, Farshid P, Naguib NNN, et al. Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies. Radiol Med (Torino). 2014;119(7):451–61. https://doi.org/10.1007/s11547-014-0415-y.

    Article  Google Scholar 

  5. Vogl TJ, Mack MG, Balzer JO, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology. 2003;229(2):457–64. https://doi.org/10.1148/radiol.2292021329.

    Article  PubMed  Google Scholar 

  6. Vogl TJ, Dommermuth A, Heinle B, et al. Colorectal cancer liver metastases: long-term survival and progression-free survival after thermal ablation using magnetic resonance–guided laser-induced interstitial thermotherapy in 594 patients. Investig Radiol. 2014;49(1):48–56. https://doi.org/10.1097/RLI.0b013e3182a6094e.

    Article  CAS  Google Scholar 

  7. Pacella CM, Valle D, Bizzarri G, et al. Percutaneous laser ablation in patients with isolated unresectable liver metastases from colorectal cancer: results of a phase II study. Acta Oncol. 2006;45(1):77–83. https://doi.org/10.1080/02841860500438029.

    Article  PubMed  Google Scholar 

  8. Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: an updated review. World J Gastrointest Pharmacol Ther. 2016;7(4):477–89. https://doi.org/10.4292/wjgpt.v7.i4.477.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Zhou Y-F. High intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol. 2011;2(1):8–27. https://doi.org/10.5306/wjco.v2.i1.8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Srikanth P, Martinie JB, Iannitti David A. Liver tumor ablation: percutaneous and open approaches. J Surg Oncol. 2009;100(8):619–34. https://doi.org/10.1002/jso.21364.

    Article  Google Scholar 

  11. Zhang L, Zhu H, Jin C, et al. High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol. 2009;19(2):437. https://doi.org/10.1007/s00330-008-1137-0.

    Article  PubMed  Google Scholar 

  12. Wu F, Wang Z-B, Chen W-Z, et al. Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology. 2005;235(2):659–67. https://doi.org/10.1148/radiol.2352030916.

    Article  PubMed  Google Scholar 

  13. Chan ACY, Cheung TT, Fan ST, et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg. 2013;257(4):686–92. https://doi.org/10.1097/SLA.0b013e3182822c02.

    Article  PubMed  Google Scholar 

  14. Kim Y, Rhim H, Choi MJ, Lim HK, Choi D. High-intensity focused ultrasound therapy: an overview for radiologists. Korean J Radiol. 2008;9(4):291–302. https://doi.org/10.3348/kjr.2008.9.4.291.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Li J-J, Xu G-L, Gu M-F, et al. Complications of high intensity focused ultrasound in patients with recurrent and metastatic abdominal tumors. World J Gastroenterol WJG. 2007;13(19):2747–51. https://doi.org/10.3748/wjg.v13.i19.2747.

    Article  PubMed  Google Scholar 

  16. Jung SE, Cho SH, Jang JH, Han J-Y. High-intensity focused ultrasound ablation in hepatic and pancreatic cancer: complications. Abdom Imaging. 2011;36(2):185–95. https://doi.org/10.1007/s00261-010-9628-2.

    Article  PubMed  Google Scholar 

  17. Dupré A, Melodelima D, Pérol D, et al. First clinical experience of intra-operative high intensity focused ultrasound in patients with colorectal liver metastases: a phase I-IIa study. PLoS ONE. 2015;10(2):e0118212. https://doi.org/10.1371/journal.pone.0118212.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Petre EN, Sofocleous C. Thermal ablation in the management of colorectal cancer patients with oligometastatic liver disease. Visc Med. 2017;33(1):62–8. https://doi.org/10.1159/000454697.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Haemmerich D, Schutt DJ. Radiofrequency ablation at low frequencies for targeted tumor heating: in-vitro and computational modeling results. IEEE Trans Biomed Eng. 2011;58(2):404–10. https://doi.org/10.1109/TBME.2010.2085081.

    Article  PubMed  Google Scholar 

  20. VanSonnenberg E, McMullen W, Solbiati L, editors. Tumor ablation: principles and practice. New York: Springer; 2004.

    Google Scholar 

  21. Hong K, Georgiades CS. Radiofrequency ablation: mechanism of action and devices. In: Hong K, Georgiades CS, editors. Percutaneous tumor ablation. 2011th ed. Stuttgart: Georg Thieme Verlag; 2011. https://doi.org/10.1055/b-0034-81499.

  22. Hong K, Georgiades CS. Percutaneous tumor ablation: strategies and techniques. New York: Thieme; 2011. http://public.eblib.com/choice/publicfullrecord.aspx?p=1250509. Accessed April 2, 2018.

    Book  Google Scholar 

  23. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. Radiology. 2000;217(3):633–46. https://doi.org/10.1148/radiology.217.3.r00dc26633.

    Article  PubMed  CAS  Google Scholar 

  24. Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities--part I. J Vasc Interv Radiol JVIR. 2001;12(9):1021–32.

    Article  CAS  PubMed  Google Scholar 

  25. Geschwind J-FH, Soulen MC. Interventional oncology: principles and practice of image-guided cancer therapy. Cambridge: Cambridge University Press; 2016.

    Book  Google Scholar 

  26. Koda M, Murawaki Y, Hirooka Y, et al. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: an analysis of 16 346 treated nodules in 13 283 patients. Hepatol Res Off J Jpn Soc Hepatol. 2012;42(11):1058–64. https://doi.org/10.1111/j.1872-034X.2012.01025.x.

    Article  Google Scholar 

  27. de Baère T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol. 2003;181(3):695–700. https://doi.org/10.2214/ajr.181.3.1810695.

    Article  PubMed  Google Scholar 

  28. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–51. https://doi.org/10.1148/radiol.2262012198.

    Article  PubMed  Google Scholar 

  29. Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2007;17(3):684–92. https://doi.org/10.1007/s00330-006-0461-5.

    Article  PubMed  Google Scholar 

  30. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies. Ann Surg. 1999;230(1):1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hildebrand P, Kleemann M, Roblick UJ, et al. Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients. Langenbeck’s Arch Surg. 2006;391(2):118–23. https://doi.org/10.1007/s00423-006-0024-x.

    Article  Google Scholar 

  32. van Amerongen MJ, van der Stok EP, Fütterer JJ, et al. Short term and long term results of patients with colorectal liver metastases undergoing surgery with or without radiofrequency ablation. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2016;42(4):523–30. https://doi.org/10.1016/j.ejso.2016.01.013.

    Article  Google Scholar 

  33. Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619–26. https://doi.org/10.1093/annonc/mds053.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Ruers T, Van Coevorden F, Punt CJA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. JNCI J Natl Cancer Inst. 2017;109(9) https://doi.org/10.1093/jnci/djx015.

  35. Nielsen K, Scheffer HJ, Volders JH, et al. Radiofrequency ablation to improve survival after conversion chemotherapy for colorectal liver metastases. World J Surg. 2016;40(8):1951–8. https://doi.org/10.1007/s00268-016-3554-6.

    Article  PubMed  Google Scholar 

  36. Valls C, Ramos E, Leiva D, Ruiz S, Martinez L, Rafecas A. Safety and efficacy of ultrasound-guided radiofrequency ablation of recurrent colorectal cancer liver metastases after hepatectomy. Scand J Surg SJS Off Organ Finn Surg Soc Scand Surg Soc. 2015;104(3):169–75. https://doi.org/10.1177/1457496914553147.

    Article  CAS  Google Scholar 

  37. Sucandy I, Cheek S, Golas BJ, Tsung A, Geller DA, Marsh JW. Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors. HPB. 2016;18(9):756–63. https://doi.org/10.1016/j.hpb.2016.06.010.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Eltawil KM, Boame N, Mimeault R, et al. Patterns of recurrence following selective intraoperative radiofrequency ablation as an adjunct to hepatic resection for colorectal liver metastases. J Surg Oncol. 2014;110(6):734–8. https://doi.org/10.1002/jso.23689.

    Article  PubMed  Google Scholar 

  39. Liu C-H, Yu C-Y, Chang W-C, Dai M-S, Hsiao C-W, Chou Y-C. Radiofrequency ablation of hepatic metastases: factors influencing local tumor progression. Ann Surg Oncol. 2014;21(9):3090–5. https://doi.org/10.1245/s10434-014-3738-y.

    Article  PubMed  Google Scholar 

  40. Hof J, Wertenbroek MWJL a E, PMJG P, Widder J, Sieders E, de Jong KP. Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. Br J Surg. 2016;103(8):1055–62. https://doi.org/10.1002/bjs.10162.

    Article  PubMed  CAS  Google Scholar 

  41. Tanis E, Nordlinger B, Mauer M, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer Oxf Engl 1990. 2014;50(5):912–9. https://doi.org/10.1016/j.ejca.2013.12.008.

    Article  CAS  Google Scholar 

  42. Wah TM, Arellano RS, Gervais DA, et al. Image-guided percutaneous radiofrequency ablation and incidence of post-radiofrequency ablation syndrome: prospective survey. Radiology. 2005;237(3):1097–102. https://doi.org/10.1148/radiol.2373042008.

    Article  PubMed  Google Scholar 

  43. Dodd GD, Napier D, Schoolfield JD, Hubbard L. Percutaneous radiofrequency ablation of hepatic tumors: postablation syndrome. AJR Am J Roentgenol. 2005;185(1):51–7. https://doi.org/10.2214/ajr.185.1.01850051.

    Article  PubMed  Google Scholar 

  44. Ikei S, Ogawa M, Beppu T, et al. Changes in IL-6, IL-8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemo-embolization therapy for hepato-cellular carcinoma. Cytokine. 1992;4(6):581–4. https://doi.org/10.1016/1043-4666(92)90023-K.

    Article  PubMed  CAS  Google Scholar 

  45. Yoshito I, Takeshi O, Naoki O, et al. Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor. Liver. 2007;19(2):97–103. https://doi.org/10.1111/j.1478-3231.1999.tb00017.x.

    Article  Google Scholar 

  46. Yukihiko M, Sumio K, Toshihiko N, et al. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. Cancer. 2006;73(1):53–7. https://doi.org/10.1002/1097-0142(19940101)73:1<53::AID-CNCR2820730111>3.0.CO;2-W.

    Article  Google Scholar 

  47. McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. Semin Interv Radiol. 2013;30(1):49–55. https://doi.org/10.1055/s-0033-1333653.

    Article  Google Scholar 

  48. Lu DSK, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol JVIR. 2003;14(10):1267–74.

    Article  PubMed  Google Scholar 

  49. Howenstein MJ, Sato KT. Complications of radiofrequency ablation of hepatic, pulmonary, and renal neoplasms. Semin Interv Radiol. 2010;27(3):285–95. https://doi.org/10.1055/s-0030-1261787.

    Article  Google Scholar 

  50. Kwon H-J, Kim PN, Byun JH, et al. Various complications of percutaneous radiofrequency ablation for hepatic tumors: radiologic findings and technical tips. Acta Radiol. 2014;55(9):1082–92. https://doi.org/10.1177/0284185113513893.

    Article  PubMed  Google Scholar 

  51. Kim KR, Thomas S. Complications of image-guided thermal ablation of liver and kidney neoplasms. Semin Interv Radiol. 2014;31(2):138–48. https://doi.org/10.1055/s-0034-1373789.

    Article  Google Scholar 

  52. Rhim H, Dodd GD, Chintapalli KN, et al. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics. 2004;24(1):41–52. https://doi.org/10.1148/rg.241025144.

    Article  PubMed  Google Scholar 

  53. Goldberg SN, Solbiati L, Halpern EF, Gazelle GS. Variables affecting proper system grounding for radiofrequency ablation in an animal model. J Vasc Interv Radiol. 2000;11(8):1069–75. https://doi.org/10.1016/S1051-0443(07)61341-4.

    Article  PubMed  CAS  Google Scholar 

  54. Kim KH, Yoon YS, Yu CS, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011;81(1):25–34. https://doi.org/10.4174/jkss.2011.81.1.25.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Hur H, Ko YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197(6):728–36. https://doi.org/10.1016/j.amjsurg.2008.04.013.

    Article  PubMed  Google Scholar 

  56. Van Tilborg AAJM, Meijerink MR, Sietses C, et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 2011;84(1002):556–65. https://doi.org/10.1259/bjr/78268814.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Veltri A, Guarnieri T, Gazzera C, et al. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival. Radiol Med (Torino). 2012;117(7):1139–51. https://doi.org/10.1007/s11547-012-0803-3.

    Article  CAS  Google Scholar 

  58. Lee H, Heo JS, Cho YB, et al. Hepatectomy vs radiofrequency ablation for colorectal liver metastasis: a propensity score analysis. World J Gastroenterol. 2015;21(11):3300–7. https://doi.org/10.3748/wjg.v21.i11.3300.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg. 2003;90(10):1240–3. https://doi.org/10.1002/bjs.4264.

    Article  PubMed  CAS  Google Scholar 

  60. Gillams AR, Lees WR. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol. 2004;14(12):2261–7. https://doi.org/10.1007/s00330-004-2416-z.

    Article  PubMed  CAS  Google Scholar 

  61. Hamada A, Yamakado K, Nakatsuka A, et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol. 2012;30(7):567–74. https://doi.org/10.1007/s11604-012-0089-0.

    Article  PubMed  Google Scholar 

  62. Boame N, Gresham G, Jonker D, Martel G, Balaa F, Asmis T. Use of chemotherapy and radiofrequency ablation to treat colorectal cancer metastases: a retrospective review of the Ottawa Hospital Cancer Centre over 7 years. Curr Oncol. 2014;21(4):e557–63. https://doi.org/10.3747/co.21.1929.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265(3):958–68. https://doi.org/10.1148/radiol.12111851.

    Article  PubMed  Google Scholar 

  64. Otto G, Düber C, Hoppe-Lotichius M, König J, Heise M, Pitton MB. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg. 2010;251(5):796–803. https://doi.org/10.1097/SLA.0b013e3181bc9fae.

    Article  PubMed  Google Scholar 

  65. Reuter NP, Woodall CE, Scoggins CR, McMasters KM, Martin RCG. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg Off J Soc Surg Aliment Tract. 2009;13(3):486–91. https://doi.org/10.1007/s11605-008-0727-0.

    Article  Google Scholar 

  66. Lee KH, Kim HO, Yoo CH, et al. Comparison of radiofrequency ablation and resection for hepatic metastasis from colorectal cancer. Korean J Gastroenterol Taehan Sohwagi Hakhoe Chi. 2012;59(3):218–23.

    Article  PubMed  Google Scholar 

  67. Ko S, Jo H, Yun S, Park E, Kim S, Seo H-I. Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. World J Gastroenterol WJG. 2014;20(2):525–31. https://doi.org/10.3748/wjg.v20.i2.525.

    Article  PubMed  Google Scholar 

  68. Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney and bone: what are the differences. Curr Probl Diagn Radiol. 2009;38(3):135–43. https://doi.org/10.1067/j.cpradiol.2007.10.001.

    Article  PubMed  PubMed Central  Google Scholar 

  69. de Baere T, Deschamps F. New tumor ablation techniques for cancer treatment (microwave, electroporation). Diagn Interv Imaging. 2014;95(7–8):677–82. https://doi.org/10.1016/j.diii.2014.04.001.

    Article  PubMed  Google Scholar 

  70. Huo YR, Eslick GD. Microwave ablation compared to radiofrequency ablation for hepatic lesions: a meta-analysis. J Vasc Interv Radiol. 2015;26(8):1139–1146.e2. https://doi.org/10.1016/j.jvir.2015.04.004.

    Article  PubMed  Google Scholar 

  71. Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(8):1054–63. https://doi.org/10.4254/wjh.v7.i8.1054.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Wolf F, Dupuy DE. Microwave ablation: mechanism of action and devices. In: Hong K, Georgiades CS, editors. Percutaneous tumor ablation. 2011th ed. Stuttgart: Georg Thieme Verlag; 2011. https://doi.org/10.1055/b-0034-81501.

  73. Brace CL. Microwave ablation technology: what every use should know. Curr Probl Diagn Radiol. 2009;38(2):61–7. https://doi.org/10.1067/j.cpradiol.2007.08.011.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Ringe KI, Lutat C, Rieder C, Schenk A, Wacker F, Raatschen H-J. Experimental evaluation of the heat sink effect in hepatic microwave ablation. PLoS ONE. 2015;10(7):e0134301. https://doi.org/10.1371/journal.pone.0134301.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Groeschl RT, Pilgrim CHC, Hanna EM, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014;259(6):1195–200. https://doi.org/10.1097/SLA.0000000000000234.

    Article  PubMed  Google Scholar 

  76. Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer. 2000;89(2):276–84.

    Article  CAS  PubMed  Google Scholar 

  77. Liu Y, Li S, Wan X, et al. Efficacy and safety of thermal ablation in patients with liver metastases. Eur J Gastroenterol Hepatol. 2013;25(4):442–6. https://doi.org/10.1097/MEG.0b013e32835cb566.

    Article  PubMed  CAS  Google Scholar 

  78. Correa-Gallego C, Fong Y, Gonen M, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol. 2014;21(13):4278–83. https://doi.org/10.1245/s10434-014-3817-0.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Martin RCG, Scoggins CR, McMasters KM. Microwave hepatic ablation: initial experience of safety and efficacy. J Surg Oncol. 2007;96(6):481–6. https://doi.org/10.1002/jso.20750.

    Article  PubMed  Google Scholar 

  80. Iannitti DA, Martin RCG, Simon CJ, et al. Hepatic tumor ablation with clustered microwave antennae: the US Phase II Trial. HPB. 2007;9(2):120–4. https://doi.org/10.1080/13651820701222677.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Zhou P, Liang P, Yu X, Wang Y, Dong B. Percutaneous microwave ablation of liver cancer adjacent to the gastrointestinal tract. J Gastrointest Surg. 2009;13(2):318. https://doi.org/10.1007/s11605-008-0710-9.

    Article  PubMed  Google Scholar 

  82. Sag AA, Selcukbiricik F, Mandel NM. Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol. 2016;22(11):3127–49. https://doi.org/10.3748/wjg.v22.i11.3127.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Adam R, Hagopian EJ, Linhares M, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg. 2002;137(12):1332–9. https://doi.org/10.1001/archsurg.137.12.1332.

    Article  PubMed  Google Scholar 

  84. Bageacu S, Kaczmarek D, Lacroix M, Dubois J, Forest J, Porcheron J. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol EJSO. 2007;33(5):590–6. https://doi.org/10.1016/j.ejso.2007.01.003.

    Article  PubMed  CAS  Google Scholar 

  85. Yu H, Burke CT. Comparison of percutaneous ablation technologies in the treatment of malignant liver tumors. Semin Interv Radiol. 2014;31(2):129–37. https://doi.org/10.1055/s-0034-1373788.

    Article  CAS  Google Scholar 

  86. Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int. 2005;95(9):1187–91. https://doi.org/10.1111/j.1464-410X.2005.05502.x.

    Article  PubMed  Google Scholar 

  87. Ryan MJ, Willatt J, Majdalany BS, et al. Ablation techniques for primary and metastatic liver tumors. World J Hepatol. 2016;8(3):191–9. https://doi.org/10.4254/wjh.v8.i3.191.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Bo YD, Philip C, Morris David L. Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma. Cancer. 2003;98(2):320–30. https://doi.org/10.1002/cncr.11498.

    Article  Google Scholar 

  89. Paganini AM, Rotundo A, Barchetti L, Lezoche E. Cryosurgical ablation of hepatic colorectal metastases. Surg Oncol. 2007;16:137–40. https://doi.org/10.1016/j.suronc.2007.10.031.

    Article  Google Scholar 

  90. Michel R, Franco DC, Pierre M, Sylvie N, Henri S, Pierre K. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002;95(11):2283–92. https://doi.org/10.1002/cncr.10973.

    Article  CAS  Google Scholar 

  91. Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg. 1999;23(2):109–14. https://doi.org/10.1007/PL00013173.

    Article  PubMed  CAS  Google Scholar 

  92. Xu K-C, Niu L-Z, He W-B, Hu Y-Z, Zuo J-S. Percutaneous cryosurgery for the treatment of hepatic colorectal metastases. World J Gastroenterol WJG. 2008;14(9):1430–6. https://doi.org/10.3748/wjg.14.1430.

    Article  PubMed  Google Scholar 

  93. Kerkar S, Carlin AM, Sohn RL, et al. Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. Surgery. 2004;136(4):770–9. https://doi.org/10.1016/j.surg.2004.07.001.

    Article  PubMed  Google Scholar 

  94. Pearson AS, Izzo F, Fleming RY, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg. 1999;178(6):592–9.

    Article  CAS  PubMed  Google Scholar 

  95. Evans J. Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM). Eur J Surg Oncol EJSO. 2007;33:S64–75. https://doi.org/10.1016/j.ejso.2007.09.027.

    Article  PubMed  Google Scholar 

  96. Clark TWI, Soulen MC. Chemical ablation of hepatocellular carcinoma. J Vasc Interv Radiol JVIR. 2002;13(9 Pt 2):S245–52.

    Article  PubMed  Google Scholar 

  97. Shiina S, Tagawa K, Unuma T, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer. 1991;68(7):1524–30.

    Article  CAS  PubMed  Google Scholar 

  98. Da Ines D, Buc E, Petitcolin V, et al. Massive hepatic necrosis with gastric, splenic, and pancreatic infarctions after ethanol ablation for hepatocellular carcinoma. J Vasc Interv Radiol JVIR. 2010;21(8):1301–5. https://doi.org/10.1016/j.jvir.2010.04.011.

    Article  PubMed  Google Scholar 

  99. Hasegawa S, Yamasaki N, Hiwaki T, et al. Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. Cancer. 1999;86(9):1682–90.

    Article  CAS  PubMed  Google Scholar 

  100. Masahiko K, Yoshikazu M, Akeri M, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer. 2000;88(3):529–37. https://doi.org/10.1002/(SICI)1097-0142(20000201)88:3<529::AID-CNCR6>3.0.CO;2-M.

    Article  Google Scholar 

  101. Scheffer HJ, Nielsen K, de Jong MC, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol JVIR. 2014;25(7):997–1011; quiz 1011. https://doi.org/10.1016/j.jvir.2014.01.028.

    Article  PubMed  Google Scholar 

  102. Davalos RV, Mir ILM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33(2):223–31.

    Article  CAS  PubMed  Google Scholar 

  103. Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat. 2005;4(6):699–705. https://doi.org/10.1177/153303460500400615.

    Article  PubMed  Google Scholar 

  104. Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng. 2006;53(7):1409–15. https://doi.org/10.1109/TBME.2006.873745.

    Article  PubMed  Google Scholar 

  105. Melikov KC, Frolov VA, Shcherbakov A, Samsonov AV, Chizmadzhev YA, Chernomordik LV. Voltage-induced nonconductive pre-pores and metastable single pores in unmodified planar lipid bilayer. Biophys J. 2001;80(4):1829–36. https://doi.org/10.1016/S0006-3495(01)76153-X.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Schmidt CR, Shires P, Mootoo M. Real-time ultrasound imaging of irreversible electroporation in a porcine liver model adequately characterizes the zone of cellular necrosis. HPB. 2012;14(2):98–102. https://doi.org/10.1111/j.1477-2574.2011.00409.x.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Thomson KR, Cheung W, Ellis SJ, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol JVIR. 2011;22(5):611–21. https://doi.org/10.1016/j.jvir.2010.12.014.

    Article  PubMed  Google Scholar 

  108. Kos B, Voigt P, Miklavcic D, Moche M. Careful treatment planning enables safe ablation of liver tumors adjacent to major blood vessels by percutaneous irreversible electroporation (IRE). Radiol Oncol. 2015;49(3):234–41. https://doi.org/10.1515/raon-2015-0031.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Cannon R, Ellis S, Hayes D, Narayanan G, Martin RCG. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544–9. https://doi.org/10.1002/jso.23280.

    Article  PubMed  Google Scholar 

  110. Kingham TP, Karkar AM, D’Angelica MI, et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg. 2012;215(3):379–87. https://doi.org/10.1016/j.jamcollsurg.2012.04.029.

    Article  PubMed  Google Scholar 

  111. Silk MT, Wimmer T, Lee KS, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol JVIR. 2014;25(1):112–8. https://doi.org/10.1016/j.jvir.2013.10.012.

    Article  PubMed  Google Scholar 

  112. Hosein PJ, Echenique A, Loaiza-Bonilla A, et al. Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. J Vasc Interv Radiol. 2014;25(8):1233–1239.e2. https://doi.org/10.1016/j.jvir.2014.04.007.

    Article  PubMed  Google Scholar 

  113. Niessen C, Beyer LP, Pregler B, et al. Percutaneous ablation of hepatic tumors using irreversible electroporation: a prospective safety and midterm efficacy study in 34 patients. J Vasc Interv Radiol JVIR. 2016;27(4):480–6. https://doi.org/10.1016/j.jvir.2015.12.025.

    Article  PubMed  Google Scholar 

  114. Frühling P, Nilsson A, Duraj F, Haglund U, Norén A. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: short to mid-term results. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2017;43(4):751–7. https://doi.org/10.1016/j.ejso.2016.12.004.

    Article  Google Scholar 

  115. Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® patient registry. Radiat Oncol Lond Engl. 2018;13:26. https://doi.org/10.1186/s13014-018-0969-2.

    Article  Google Scholar 

  116. Berkovic P, Gulyban A, Nguyen PV, et al. Stereotactic robotic body radiotherapy for patients with unresectable hepatic oligorecurrence. Clin Colorectal Cancer. 2017;16(4):349–357.e1. https://doi.org/10.1016/j.clcc.2017.03.006.

    Article  PubMed  Google Scholar 

  117. Joo JH, Park J, Kim JC, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol. 2017;99(4):876–83. https://doi.org/10.1016/j.ijrobp.2017.07.030.

    Article  Google Scholar 

  118. Gani F, Thompson VM, Bentrem DJ, Hall BL, Pitt HA, Pawlik TM. Patterns of hepatic resections in North America: use of concurrent partial resections and ablations. HPB. 2016;18(10):813–20. https://doi.org/10.1016/j.hpb.2016.06.002.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Bai H, Huangz X, Jing L, Zeng Q, Han L. The effect of radiofrequency ablation vs. liver resection on survival outcome of colorectal liver metastases (CRLM): a meta-analysis. Hepato-Gastroenterology. 2015;62(138):373–7.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

    Mariana I. Chavez, Christopher Coon & T. Clark Gamblin

Authors
  1. Mariana I. Chavez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher Coon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Clark Gamblin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Clark Gamblin .

Editor information

Editors and Affiliations

  1. National Cancer Institute, Rio de Janeiro, Brazil

    Mauro Monteiro Correia

  2. Banner MD Anderson Cancer Center, Phoenix, AZ, USA

    Michael A. Choti

  3. Virginia Mason Medical Center, Seattle, WA, USA

    Flavio G. Rocha

  4. Center for Advanced Treatment of HBP Diseases, Ageo Central General Hospital, Ageo Shi, Saitama, Japan

    Go Wakabayashi

Rights and permissions

Reprints and permissions

Copyright information

© 2020 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chavez, M.I., Coon, C., Gamblin, T.C. (2020). Ablative Techniques for CRLM: Alone or in Association. In: Correia, M., Choti, M., Rocha, F., Wakabayashi, G. (eds) Colorectal Cancer Liver Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-25486-5_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25486-5_36

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25485-8

  • Online ISBN: 978-3-030-25486-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation